Advanced search
Publication Cover
Blood Pressure Volume 18, 2009 - Issue sup1
Submit an article Journal homepage
376
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study

Michel P. Hermans St-Luc University Hospital, Catholic University of Louvain, Brussels, BelgiumCorrespondence[email protected]
,
Olivier De Coster Clinique St-Etienne, Brussels, Belgium
,
Laurence Seidel Medical Informatics and Biostatistics, University of Liège, Liège, Belgium
,
Adelin Albert Medical Informatics and Biostatistics, University of Liège, Liège, Belgium
&
Philippe Van De Borne Erasme University Hospital, Free University of Brussels, Brussels, Belgium
Pages 5-14 | Received 28 Feb 2009, Accepted 01 Jun 2009, Published online: 18 Nov 2009

References

  • The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007; 25:1105–1187.
  • Fourth Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Cardiovascular Disease Prevention in Clinical Practice (European Guidelines on). Eur J Cardiovasc Prev Rehab. 2007; 14Suppl. 2:S1–S113.
  • Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri E. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987; 84:9265–9269.
  • Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: a selective beta(1)-adrenergic receptor antag onist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide. 2002; 7:75–82.
  • Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995; 274:1067–1071.
  • Van Bortel LM, Van Merode T, Smeets FA. Nebivolol improves the vessel wall properties of the common carotid artery. Drug Invest. 1991; 3:61–63.
  • Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005; 1812 Pt 2:177S–183S.
  • Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007; 67:1097–1107.
  • Wojciechowski D, Papademetriou V. Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther. 2008; 6:471–479.
  • Williams GH. Quality of Life and its impact on hypertensive patients. Am J Med. 1987; 82:98–105.
  • Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective b-blockers in the treatment of hypertension. High Blood Press Cardiovasc Prev. 2005; 12:27–35.
  • Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, Edes I. for The NEBIS Investigators; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc Drugs Ther. 2003; 17:257–263.
  • Uhliř O, Fejfuš M, Havránek K, Lefflerová K, Vojáček J, Widimskyˇ J, Winterová J, Zeman K. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest 3. 1991; S1:107–110.
  • Van Bortel LM, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther. 1992; 6:239–247.
  • Celik T, Yuksel UC, Iyisoy A, Kursaklioglu H, Ozcan O, Kilic S, Ozmen N, Isik E. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertension. 2006; 24:591–596.
  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, . National Heart, Lung, and Blood Institute. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003; 289:2560–2572.
  • Breed JGS, Ciampricotti R, Tromp UP, Valster PA, Lageweg B, Van Bortel LMAB. Quality of life perception during antihypertensive treatment. A comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992; 20:750–755.
  • Bulpitt CI, Fletcher AL. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol. 1990; 30:353–364.
  • Van Bortel LM, Bulpitt CJ, Rici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005; 18:1060–1066.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.